GLYC - GlycoMimetics names Harout Semerjian as chief executive officer

GlycoMimetics (NASDAQ:GLYC) announces the appointment of Harout Semerjian as the company's chief executive officer. Semerjian will succeed retiring founding CEO of the company Rachel King. He is a seasoned executive with strong oncology commercialization experience, will lead the company as it advances its registrational trials on its lead clinical candidate, uproleselan, in acute myeloid leukemia (AML), the company said. King, who has served as CEO for 18 years, has decided to retire for personal reasons and will continue her involvement with the company through her role on the Board of Directors and serving as an advisor during this transition, GlycoMimetics added. Shares up more than 1% post market.

For further details see:

GlycoMimetics names Harout Semerjian as chief executive officer